This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cerlapirdine
- DrugBank Accession Number
- DB12229
- Background
Cerlapirdine has been investigated for the treatment of Alzheimer Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Cerlapirdine (DB12229)
- Weight
- Average: 409.5
Monoisotopic: 409.146012787 - Chemical Formula
- C22H23N3O3S
- Synonyms
- Cerlapirdine
- External IDs
- PF-05212365
- SAM-531
- SAM-531 FREE BASE
- WAY-262,531
- WAY-262531
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Cerlapirdine is combined with 1,2-Benzodiazepine. Acenocoumarol The risk or severity of adverse effects can be increased when Cerlapirdine is combined with Acenocoumarol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Cerlapirdine. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Cerlapirdine. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Cerlapirdine. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Cerlapirdine. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Cerlapirdine. Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Cerlapirdine. Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Cerlapirdine. Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Cerlapirdine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cerlapirdine Hydrochloride 2VCB4037GE 925447-04-7 RNGAZJUESDPASQ-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Naphthalenes
- Sub Class
- Not Available
- Direct Parent
- Naphthalenes
- Alternative Parents
- Indazoles / Phenol ethers / Alkyl aryl ethers / Sulfones / Pyrazoles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzopyrazole / Ether / Heteroaromatic compound / Hydrocarbon derivative / Indazole
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EK40PJ0V49
- CAS number
- 925448-93-7
- InChI Key
- NXQGEDVQXVTCDA-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
- IUPAC Name
- dimethyl(3-{[3-(naphthalene-1-sulfonyl)-1H-indazol-5-yl]oxy}propyl)amine
- SMILES
- CN(C)CCCOC1=CC=C2NN=C(C2=C1)S(=O)(=O)C1=C2C=CC=CC2=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 16071605
- PubChem Substance
- 347828508
- ChemSpider
- 17231095
- BindingDB
- 50044616
- ChEMBL
- CHEMBL2103880
- Wikipedia
- Cerlapirdine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Not Available Alzheimer's Disease (AD) 1 2 Terminated Treatment Alzheimer's Disease (AD) 1 1 Completed Not Available Adults / Healthy Subjects (HS) 1 1 Completed Basic Science Healthy Subjects (HS) 1 1 Completed Health Services Research Alzheimer's Disease (AD) 1 1 Completed Treatment Alzheimer's Disease (AD) 6 1 Completed Treatment Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00476 mg/mL ALOGPS logP 3.4 ALOGPS logP 3.49 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 9.13 Chemaxon pKa (Strongest Basic) 7.83 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 75.29 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 115.72 m3·mol-1 Chemaxon Polarizability 43.36 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:41 / Updated at February 21, 2021 18:53